SEC Form 10-K filed by Vivani Medical Inc.
$VANI
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)
SC 13D - Vivani Medical, Inc. (0001266806) (Subject)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
10-K - Vivani Medical, Inc. (0001266806) (Filer)
8-K - Vivani Medical, Inc. (0001266806) (Filer)
Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam Mendelsohn, Ph.D. and CMO Lisa Porter, M.D. to discuss the Company's LIBERATE-1 clinical trial from which topline data is anticipated in mid-year 2025 ALAMEDA, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced its participation in a virtual fireside chat hosted by Yi Chen, Ph.D., CFA, Managing Director of Equity Research at H.C. Wainwright & Company. As part of t
ALAMEDA, Calif. and SAN FRANCISCO, April 15, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc. ("Okava"), a clinical-stage company focused on diseases of aging in dogs and cats, today announced an expansion of their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Vivani and Okava initiated their collaboration in 2019, with a focus on developing OKV-119 for cardiometabolic conditions in cats. OKV-119 leverages Viva
Successful initial administration and full enrollment in first-in-human LIBERATE-1™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 (semaglutide implant) preclinical weight loss data comparable to injections of semaglutide, active ingredient in Ozempic®/Wegovy®, with potential for once-yearly dosing Additional $8.25M equity financing which secures solid financial position into the second quarter of 2026, supporting further development of NPM-139 and NPM-115 programs in chronic weight management ALAMEDA, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"),
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)
4 - Vivani Medical, Inc. (0001266806) (Issuer)